Health State Utility Values for Age-Related Macular Degeneration: Review and Advice by Butt, T et al.
1 
 
Title: Health state utility values for age-related macular degeneration: 
review and advice 
 
Short title: Health state utility values for AMD 
Authors: Thomas Butt1*, Adnan Tufail1,2, Gary Rubin1 
*Corresponding Author 
Affiliations: [1] UCL Institute of Ophthalmology, London, United Kingdom, [2] Moorfields Eye 
Hospital, London, United Kingdom 
Correspondence:  
UCL Institute of Ophthalmology, 11-43 Bath Street, London. EC1V 9EL. United Kingdom 
thomas.butt.10@ucl.ac.uk 
Compliance with Ethical Standards:  
TB reports employment from BioMarin Europe, outside the submitted work. This work received no 
specific funding. AT and GSR receive a proportion of their funding from the Department of Health’s 
NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of 
Ophthalmology. 
Author Contributions: 
TB, AT and GR developed the review concept. TB conducted the searches and drafted the 
manuscript. All authors reviewed the search results and approved the final manuscript. TB is the 
manuscript guarantor.  
2 
 
Abstract 
Health state utility values are a major source of uncertainty in economic evaluations of interventions 
for age-related macular degeneration (AMD). This review identifies and critiques published utility 
values and methods for eliciting de-novo utility values in AMD. We describe how utility values have 
been used in health care decision making and provide guidance on the choice of utility values for 
future economic evaluations for AMD. Literature was searched using PubMed and health technology 
assessments (HTA) were searched using HTA agency websites to identify articles reporting utility 
values or approaches to derive utility values in AMD and articles applying utility values for use in 
health care decision making.s71 studies qualified for data extraction of which 22 were classified as 
containing utility values and/or elicitation methods relevant to AMD, while 49 were classified as 
using utility values in decision-making. A large number of studies have elicited utility values for AMD, 
although those applied to decision making have focused on a few of these. There is an appreciation 
of the challenges in the measurement and valuation of health states, with recent studies addressing 
challenges such as the insensitivity of generic health-related quality of life (HRQoL) questionnaires 
and utility in the worse seeing eye. We would encourage careful consideration when choosing utility 
values in decision making and an explicit critique of their applicability to the decision problem. 
 
Key Points for Decision Makers: 
 There is a large body of literature describing utility values in AMD. 
 Challenges for estimating utilities in AMD include the insensitivity of generic HRQoL 
questionnaires and valuing vision in the worse seeing eye. 
 Economic evaluations of interventions for AMD have relied on a small number of utility 
studies, which may not meet some important criteria.  
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1. Background 
Age-related macular degeneration (AMD) is a common cause of visual impairment in older adults. 
Untreated, the disease leads to the progressive loss of central vision and impacts on ability to 
perform daily activities such as recognising faces and reading.[1] 
The disease covers two forms with different underlying causes: Dry AMD begins with drusen in the 
macular (age-related maculopathy) which may develop into geographic atrophy. There is currently 
no treatment for dry AMD. Wet (neovascular) AMD is caused by abnormal blood vessel growth. A 
number of treatments have become available for neovascular AMD over the past 10 years: firstly 
verteporfin photodynamic therapy (vPDT), and later a number of anti-vascular endothelial growth 
factors (anti-VEGFs) including ranibizumab (Lucentis), bevacizumab (Avastin) and aflibercept (Eylea), 
stimulating interest in the incremental value of these new treatments over the standard of care. 
Cost-utility analysis has been widely used to assess relative value of these interventions. A recent 
review of economic models comparing treatments for AMD identified 36 studies of which all but 3 
reported costs per quality-adjusted life year (QALY).[2] 
QALYs are calculated by weighting each year of life lived using a utility score. Utility scores are 
anchored so that 1 is perfect health and 0 is equivalent to the state of death. Multiplying time in a 
health state by the health state utility value, 1 year of life lived in perfect health is equal to 1 
QALY.[3]The term ‘utility’ in cost-utility analysis and its theory is based on von Neumann-
Morgenstern (vN-M) utility theory. The normative model for utility theory, the model for how a 
rational individual ought to behave, is that utility scores represent the strength of an individual’s 
preference when faced with uncertainty for a given outcome, in this case a health state.[4] 
Within economic models, utilities have been identified as major sources of uncertainty: both in 
terms of the sensitivity of model outputs to the choice of utility values and in terms of the methods 
by which utility values are elicited.[2] 
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The importance of utility values in economic evaluations of interventions for AMD stems from the 
nature of the condition:  the disease is characterised by the progressive loss of central vision, which 
severely limits the ability to perform daily activities and consequently has a major impact on quality 
of life. There have been two relevant reviews to date covering utility values in AMD. Pearson et al. 
systematically reviewed utility values specific to wet AMD and evaluated these against the NICE 
reference case. [5]  They recommended the time trade-off (TTO) and Health Utilities Index Mark 3 
(HUI3) for use in economic evaluations based on the correlation of these measures with visual 
acuity. Poku et al. systematically reviewed articles reporting the relationship between visual acuity 
and utility across AMD, diabetic retinopathy (DR) and diabetic macular oedema (DMO).[6] They 
found that self-reported time trade-off was most strongly associated with visual acuity and that 
utility values had a higher association with the better seeing eye than the worse seeing eye.  
Also of note, Tosh et al. reviewed generic preference-based measures of health-related quality of life 
(HRQoL) in visual disorders, finding that the performance of the EQ-5D was mixed, and that more 
head to head comparisons were needed between the EQ-5D, the SF-6D and the HUI-3.[7] 
This review aims to identify and critique published utility values and methods for eliciting de-novo 
utility values in AMD. The review describes how utility values have been used in economic models 
and health care decision making and provides guidance to the choice of utility values for future 
economic evaluations for AMD. 
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2. Methods 
A search was conducted in PubMed to determine what approaches have been used to derive utility 
values in AMD and how utility values have been used in health care decision making. The search was 
supplemented with HTA agency websites to support the latter aim. 
Title and abstracts were searched in PubMed on 3 January 2016. No date or language restrictions 
were applied to the searches. Terms covering AMD and utility were combined using the following 
search strategy: 
[(macular degeneration) OR (geographic atrophy)] AND [(qaly) OR (quality-adjusted life year) OR 
(utility)] 
Key HTA agency websites (UK: National Institute of Health and Care Excellence (NICE), Sweden: 
Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), 
Australia: Medical Services Advisory Committee (MSAC), Canada: Canadian Agency for Drugs and 
Technologies in Health (CADTH)) were searched for technology appraisals in English language 
covering interventions for macular degeneration. 
A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) scheme (Table 1) 
illustrates the included studies after title/abstract and full text reviews. Of the 206 studies identified, 
113 studies were excluded after review of abstracts and titles. Reasons for exclusion included the 
topic not relating to utility, the disease not covering AMD, there being no primary data (e.g. letter or 
review) and the language not being English. After full text review, a further 23 studies were excluded 
due to the topic not relating to utility, the type of article being a letter or review with no primary 
data, or the study being a duplicate.  
Included studies were classified by those reporting utilities (utility sets or methods to derive utility 
sets) and by those applying utilities to decision making (economic evaluations and HTAs). Two data 
extraction sheets were used to classify the data from the studies. In the first extraction sheet key 
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methodological parameters such as elicitation technique, geography and sample were recorded for 
studies reporting utility sets or methods to derive utility sets. In the second extraction sheet utility 
values used in the base case were recorded for economic evaluations and HTAs. 
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3. Results 
70 studies were selected for data extraction of which 22 were classified as containing utility values 
and/or elicitation methods relevant to AMD, while 48 were classified as using utility values in 
decision-making. A small number of the latter also collected de novo utilities. Table 2 and Table 3 
summarise the key components of the included studies. 
1. Utility values and elicitation methods 
The majority of utility values identified were classified by health states. This is likely due to the 
majority of economic models for AMD being health state transition models. The health states tend 
to be defined by visual function parameters, chiefly visual acuity, although contrast sensitivity has 
also been associated with utility and research has suggested that contrast sensitivity may be better 
correlated with utility than visual acuity.[8, 9] 
Early studies focused on the elicitation of utilities directly from patients. For example, Brown et al. 
elicited utilities from patients using the TTO and SG.[10] Utilities have also been elicited via tariffs of 
preference-based questionnaires,[8] from healthy volunteers via simulation contact lenses[11] and 
from ophthalmologists.[12] 
The most common elicitation method was the TTO, which was used in 16 of the 22 studies. Anchors 
of perfect health/ death and perfect vision/ blindness have been used to elicit utilities. (Table 2) It 
has been shown that different utility values can be obtained depending on the anchor. For example, 
Au Eong et al. obtained a mean utility of 0.91 using the standard gamble (SG) anchored to blindness 
and 0.86 using the SG anchored to death.[13] 
Samples for deriving utility estimates ranged in size depending on the research question, with the 
largest being a 1,829 AMD patients who completed the SF-36 as part of the Verteporfin 
Photodynamic Therapy Cohort Study.[14] (Table 2) 
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Utilities are available for a number of countries (Table 2). The USA and the UK were the most 
common countries for utilities, which is indicative of the location of prominent health economic 
research groups, but may also be a function of an English language search strategy. 
Lee et al. found considerable variation in the utility values reported, with values differing by as much 
as two-fold between studies.[15] A number of studies used several methods and presented different 
utility values by method, with several studies making the differences between elicitation methods a 
particular focus. Yanagi et al. found that TTO-derived utilities correlated more strongly with better 
seeing eye VA than SG-derived utilities in a study of Japanese patients.[16] Stein et al. investigated 
the impact of eliciting utilities for AMD health states from different groups. They found that patients 
rated their health more severely than clinicians or the general population using the TTO.[17] 
Some studies highlighted the challenges of using generic preference-based questionnaires to derive 
utilities in AMD and proposed recommendations and/or methodological improvements. 
Espallargues et al. elicited utilities for several generic preference based questionnaires and the TTO, 
concluding that the HUI-3 would be the preferred measure.[8] One study provided a mapping 
algorithm to derive utilities from the NEI-VFQ-25. Payakachat et al. predicted EQ-5D utility values 
from the NEI-VFQ 25 in a population of patients with wet AMD.[18] 
The multi-factorial considerations of utility in AMD have been addressed by a number of papers. 
Most utility values were associated with the better seeing eye. Utility values can vary considerably 
depending on whether the better seeing or worse seeing eye is affected and utility values for the 
worse seeing eye are available.[19] Skalicky et al. investigated the impact of ocular comorbidities on 
utility, chiefly AMD in glaucoma patients.[20] While adverse events have been elicited including 
event-based utility decrements. For example Mowatt et al. applied utility weights based on Brown et 
al. for health states and then decrements for adverse events including cataract, endophthalmitis, 
retinal detachment and uveitis.[21] 
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2. Utility values in decision making 
All but one of the studies identified in this review that applied utilities to decision making took the 
form of cost-utility analyses. One study compared QALYs without including costs: Kim et al. 
investigated the impact of PDT on AMD patients in Korea.[22] 
Most studies applied utilities from Brown et al. based on TTO in a sample of AMD patients.[10] 
(Table 3) These utility values were derived from a mixed population of wet and dry AMD, whereas 
the decision problem of many papers was often for a specific form of AMD. Studies assessed a 
number of treatments including anti-VEGFs, PDT and screening, although there was no trend to 
apply different utility weights based on the intervention under consideration. Neither was there a 
trend to apply different utility values by geography of study, despite values being available for 
several geographies.  
Studies found that the choice of utility set could result in very different estimated QALY gains for 
similar decision problems. Kymes et al. estimated an incremental QALY gain of 1.15 for ranibizumab 
or bevacizumab for AMD in their report for CADTH[23] compared with NICE’s estimates of 
incremental QALYs of 0.45 to 0.73, depending upon the scenario.[24] They concluded that the likely 
reason for the difference was the utility sets used (Espallargues et al. for NICE and Sharma et al. for 
CADTH), although the two models varied in other inputs too.[8, 25]  
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3. Discussion 
Utility values have been widely used in decision making in AMD and the choice of utility values has 
been frequently highlighted as having a major impact on the results of economic evaluations.  
These evaluations have focused on a few utility sets[10] while other utility sets have not been used 
to date[18]. Such a focus on a limited range of utility sets improves comparability between studies, 
although the trade-off is to accept the limitations of the utility values used in terms of methodology 
and sample. 
The most frequently used utility values from Brown et al. were derived for visual acuity health states 
from a mixed sample of wet and dry AMD patients in the USA.[10] While many economic models 
focused on specific forms of AMD (wet in the case of evaluations of anti-VEGF therapies) and 
covered different geographies, most economic models applied the utility values from this small 
sample of US patients with wet and dry AMD. 
Some papers sought to provide guidance on utility values although there is little evidence that this 
has been followed. Notably Espallargues et al. concluded that the HUI-3 would be preferred for use 
in economic evaluation due to its stronger correlation with visual acuity and contrast sensitivity.[8] 
However, the HUI-3 was rarely used by studies since (or prior to) this publication. 
Some articles that contain relevant guidance on utility values in AMD may not have been picked up 
by the search strategy if they did not mention the condition explicitly. For example, in an attempt to 
address the insensitivity of generic HRQoL questionnaires in vision disorders, a vision ‘bolt-on’ was 
developed for the EQ-5D 3L.[26] The EQ-5D+V has been valued in the general population, although 
the questionnaire content is yet to be validated in patients with vision disorders. The focus of this 
review was utility values for AMD, therefore it did not include articles on other vision disorders, 
although many of the findings can be applied to vision disorders more broadly. 
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What makes ‘good’ utility values? The strength of utility values depends on the context of use. 
However a few general guidelines can be given for choosing utility values for any condition and a few 
more specific guidelines can be given for AMD. 
Generally, the choice of utility value should reflect the perspective of the decision problem. For 
example, decisions concerning publically funded health care systems should apply utility values that 
are representative of the preferences of the general population.[27] Utility values are known to vary 
by geography, so where possible, preferences should reflect the geography of the decision problem. 
The measurement of health states on which the utility values are based should be based on the 
patient-reported health of subjects who are experiencing the health state in question. 
For AMD there is are a number of utility values available that meet the needs of different 
geographies and various health states as defined by type of disease (wet or dry AMD) and by levels 
of visual function. There remain a number of issues that are specific to AMD that should be 
considered when interpreting or applying utility values: 
1. Adaptation 
For chronic conditions, the concept of adaptation exists, whereby patients may adapt to their 
condition and therefore rate their health state less severely than a member of the community who is 
unaffected by the condition.[28] 
 In AMD patients there is evidence that patients rate their health state more severely than the public 
or their clinicians, which would run contrary to the theory of adaptation.[17] For these reasons, we 
urge careful consideration of the choice of patient or general public utility values and note that this 
will be further influenced by the perspective of the evaluation. 
2. Age and co-morbidities 
Utility values should be collected on a scale anchored by perfect health and dead.[3] AMD tends to 
affect older people who may be experiencing one or more other diseases and the impact of co-
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morbidities makes the interpretation of absolute utility values challenging. While cost-utility analysis 
requires only the change in utility over time, comorbidities may increase the variability in utilities 
collected and so require larger sample sizes to collect robust utility sets. 
3. Better or worse seeing eye 
Whether the presenting eye is the better or worse-seeing eye is a significant determinant of the 
impact of the disease on a patient’s quality of life. AMD in the better seeing eye has a greater impact 
on a patient than AMD in the worse seeing eye, although vision in both eyes can have an 
independent impact, and this is reflected in the utility values for each eye.[29] Utility values should 
incorporate the impact of the disease on the patient’s daily life, so should account for vision in both 
eyes and their interaction. 
4. Wet/ dry AMD 
Utility values are available for samples of wet AMD, dry AMD and mixed samples. Generally the most 
appropriate utility set will be that which matches the condition in the decision problem. Most, but 
not all, decision problems have related to treatments for wet AMD due to the emergence of anti-
VEGF therapies and therefore it would have been expected that utility sets using a wet AMD 
population would have been used most frequently. However, the most frequently used utility sets 
were from a mixed sample.[10] 
5. Visual function 
Most economic models are based on visual function, with visual acuity being the most common 
measure. Utility values are most frequently available for visual acuity. Utility values are also available 
for contrast sensitivity, although the potential to use these in economic evaluation is limited by the 
lack of outcomes data collected on the parameter in trials or routine practice. The choice of visual 
function parameter should be driven by an understanding of the association between visual function 
and utility as well as the availability of that parameter in the dataset of interest. 
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5. Conclusion 
There is a large body of literature describing utility values in AMD. An appreciation of the challenges 
in the measurement and valuation of health states is evident from the papers identified in this 
review, with recent studies addressing challenges such as the insensitivity of generic HRQoL 
questionnaires and utility in the worse seeing eye. However, the use of utility values in decision 
making has seemingly not kept pace with these methodological developments with a reliance on a 
small number of utility studies. 
The choice of utility value should be based on a number of considerations, some positive and others 
normative. It is unlikely that all can be fully addressed by one utility set, therefore we would 
encourage careful consideration when choosing utility values in decision making, an explicit critique 
of their applicability to the decision problem and the impact of alternative utility sets should be 
presented within sensitivity analysis.  
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Tables 
Table 1: PRISMA scheme 
Stage PubMed HTA websites 
Articles identified in search 199 7 
Included = 206 
Level 1: Title and abstract review Excluded = 113. Reason: Topic not utility (84), Disease not 
macular degeneration (15), Review/letter (3), Language not 
English (10) 
Included = 93 
Level 2: Full text review Excluded = 23. Reason: Topic not utility (6), Review/letter 
(12), Duplicate (5) 
Included = 70 
Articles included in review Utility/methods = 22 
Decision-making = 48 
 
Table 2: Utility values or methodological studies 
Reference* Valuation 
technique 
Population Sample size Geography Associations 
Skalicky et 
al.[20] 
Visual 
Function 
Questionnaire 
Utility Index 
Glaucoma 
patients with 
AMD 
200 glaucoma 
patients of which 
73 had AMD 
United 
Kingdom 
N/A 
Butt et 
al.[30] 
N/A Healthy 
volunteers 
5 United 
Kingdom 
N/A 
Butt et 
al.[31] 
EQ-5D, SF-6D, 
TTO, VAS 
Patients with 
AMD 
60 United 
Kingdom 
BSE VA 
Finger et 
al.[19] 
EQ-5D, TTO, 
SG, VAS 
Patients with 
nAMD 
55 Germany BSE VA, WSE 
VA 
Au Eong et 
al.[13] 
EQ-5D, TTO, 
SG 
Patients with 
AMD 
338 Singapore BSE VA, WSE 
VA, weighted 
average of 
both eyes VA 
Yanagi et 
al.[16]  
TTO, SG Patients with 
bilateral 
exudative AMD 
48 Japan BSE VA 
Reeves et 
al.[14] 
SF-6D Patients with 
nAMD 
1829 United 
Kingdom 
VA, CS 
Payakachat 
et al.[18] 
Mapping to 
EQ-5D 
Patients with wet 
AMD 
151 Australia, 
the 
Netherlands,  
United 
Kingdom, 
United 
States 
NEI VFQ-25 
Czoski-
Murray et 
al.[11] 
TTO for 
simulated 
health states 
Healthy 
volunteers 
108 United 
Kingdom 
BSE VA 
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Real et 
al.[32] 
TTO Patients with 
AMD, DR, retinal 
tear, retinal 
vascular 
obstruction, 
uveitis, macular 
oedema, macular 
pucker, other 
51 AMD United 
States 
N/A 
Lee et 
al.[15] 
SG Patients with 
AMD, DR, 
glaucoma, 
cataract or 
refractive error 
44 AMD United 
States 
BSE VA 
Sahel et 
al.[29] 
HUI-3 Patients with wet 
AMD 
360 France, 
Germany, 
Italy 
BSE VA, WSE 
VA 
Aspinall et 
al.[33] 
TTO, conjoint 
analysis 
Patients with 
AMD 
122 United 
Kingdom 
Binocular VA, 
binocular CS, 
AMD grade 
Bansback et 
al.[9] 
HUI-3, TTO Patients with 
AMD 
209 United 
Kingdom 
BSE VA, WSE 
VA, binocular 
VA, binocular 
CS 
Brown et 
al.[34] 
TTO Patients with 
AMD, public, 
clinicians and 
ophthalmologists 
82 patients, 142 
community, 62 
clinicians, 46 
ophthalmologists 
United 
States 
BSE VA 
Espallargues 
et al.[8] 
EQ-5D, SF-6D, 
HUI-3, VAS, 
TTO 
Patients with 
AMD 
209 United 
Kingdom 
BSE VA, 
Binocular CS, 
VF-14 
Stein et 
al.[17] 
TTO Patients with 
AMD, healthy 
volunteers, 
clinicians 
115 patients, 
142 volunteers, 
62 clinicians 
United 
States 
BSE VA 
Brown et 
al.[35] 
TTO Patients with 
AMD or DR 
246 AMD United 
States 
BSE VA 
Hollands et 
al.[36] 
TTO Patients with DR 
and AMD 
14 AMD Canada N/A 
Sharma et 
al.[25] 
TTO Patients with 
ocular 
conditions, 
including 
macular 
degeneration, 
cataract, 
glaucoma and 
diabetic 
retinopathy 
239 United 
States 
BSE VA 
Brown et 
al.[12] 
TTO, SG Ophthalmologists 46 United 
States 
BSE VA 
Brown et TTO, SG Patients with 80 United BSE VA 
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al.[10] AMD States 
TTO = time trade-off, SG = standard gamble, VAS = visual analogue scale, VA = visual acuity, CS = 
contrast sensitivity, BSE = better seeing eye, WSE = worse seeing eye. *ordered by year of 
publication. 
 
Table 3: Utility values used in decision making 
Reference* Intervention Country Utility values 
Ma et al.[37] 
Cataract surgery in advanced 
AMD 
China 
Within study (TTO)[37] 
Chan et al.[38] 
Screening for intermediate 
AMD during DR screening 
Hong Kong 
Brown 2005, assumptions 
Butt et al.[39] Ranibizumab for AMD United Kingdom Brown 2000[10] 
Tamura et al.[40] Screening for AMD 
Japan Brown 1999, Brown 
2000[10] 
Mowatt et al.[21] 
OCT for diagnosis, monitoring 
and treatment decisions in 
AMD 
United Kingdom 
 Brown 2000[10], Brown 
2007 
Dakin et al.[41] 
Ranibizumab and 
bevacizumab for AMD 
United Kingdom 
Within study (EQ-5D) 
Elshout et al.[42] Aflibercept for AMD Netherlands Within study (HUI-3) 
Butt et al.[43] Bevacizumab for AMD United Kingdom Espallargues 2005[8] 
Stein et al.[44] 
Bevacizumab and ranibizumab 
for newly diagnosed AMD 
United States HS: Brown, Side effects: 
Aaberg, Bajaj, Brown, 
Freeman 
Reeves et al.[14] Verteporfin PDT for AMD United Kingdom Within study (SF-6D) 
Athanasakis et al.[45] Ranibizumab for AMD Greece Brown 2000[10] 
Brown et al.[46] 
Implantable miniature 
telescope for end-stage AMD 
United States Sharma 2002, Brown 1999, 
Sharma 2000,[25] Brown 
1999, Brown 2000[10], 
Brown 2001, Brown 2001, 
Nrown 2002 
Patel et al.[47] Bevacizumab for AMD United States Modified from Brown 2000 
Kim et al.[22] PDT for AMD Korea Within study (EQ-5D) 
Neubauer et al.[48]  Ranibizumab for nAMD Germany Brown 2000[10] 
Hodge et al.[49] 
Pharmacologic management 
of nAMD 
Canada 
Sharma 2000[25] 
Neubauer et al.[50] 
Retinal pigment epithelium 
and choroid translocation for 
nAMD 
Germany, United States 
Bansback 2007[9] 
Grieve et al.[51] Verteporfin PDT for nAMD United Kingdom Within study (SF-6D) 
Gower et al.[52] 
Pegaptanib and ranibizumab 
for nAMD 
United States 
Brown 2002, Brown 2003 
Hernandez-Pastor et al.[53] Ranibizumab for nAMD Spain Brown 2000[10] 
Karnon et al.[54] Screening for AMD 
United Kingdom Espallargues 2005,[8] Brown 
2000[10] 
Fletcher et al.[55] Treatments for nAMD Not specified Sharma 2000[25] 
Hurley et al.[56] 
Smoking cessation to prevent 
AMD 
United States 
Brown 2000[10] 
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Hurley et al.[57] Ranibizumab for nAMD United States Brown 2000[10] 
Bojke et al.[58] Screening for AMD United Kingdom Brown 2001[59] 
Javitt et al.[60] 
Early treatment of AMD with 
pegaptanib 
United States 
Brown 2000[10] 
Earnshaw et al.[61] Pegaptanib for AMD Canada Brown 2000[10] 
Brown et al.[62] Ranibizumab for AMD United States Brown 2001[59] 
Wolowacz et al.[63] Pegaptanib for AMD United Kingdom Brown 2000[10] 
Raftery et al.[64] Ranibizumab for AMD United Kingdom Brown 2000[10] 
Brown et al. Interventions for AMD United States Brown 2001[59] 
Rein et al.[65] Vitamin therapy for AMD United States Brown 2003 
Bansback  et al.[66] Verteporfin PDT for AMD United Kingdom Espallargues 2005[8] 
Brown et al. Verteporfin PDT for nAMD United States Brown 2001[59] 
Sharma et al.[67] anecortave acetate for AMD Not specified Within study (TTO) 
Trevithick et al.[68] Vitamin therapy for AMD Canada Not specified 
Smith et al.[69] Verteporfin PDT for AMD United Kingdom Brown 2000[10] 
Hopley et al.[70] Verteporfin PDT for nAMD 
Australia and United 
Kingdom Brown 2000[10] 
Hopley et al.[71] 
Screening and 
zinc/antioxidants for AMD 
Australia and United 
Kingdom Sharma 2000[25] 
Busbee et al.[72] Laser photocoagulation United States Brown 1999 
Meads et al.[73] Verteporfin PDT for AMD United Kingdom Brown 2000[10] 
Sharma et al.[74] Verteporfin PDT for AMD United States Brown 2000[10] 
Brown et al.[75] Laser photocoagulation United States Brown 1999 
NICE TA298 
Ranibizumab for treating 
choroidal neovascularisation 
associated with pathological 
myopia 
United Kingdom 
Czoski Murray 2009[11] 
NICE TA294 Aflibercept for wet AMD 
United Kingdom VIEW 2 study (EQ-5D), AEs: 
Brown 2007[62], Gower 
2010[52]. 
NICE TA155 
Ranibizumab and pegaptanib 
for AMD 
United Kingdom Czoski Murray 2009,[11] 
Espallargues 2005,[8] Brown 
2000[10] 
NICE TA68 PDT for AMD United Kingdom Brown 2000[10] 
CADTH 2009 
Pharmacologic management 
in nAMD 
Canada 
Sharma 2000[25] 
 
*ordered by year of publication. 
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